Intimation of Allotment of equity shares pursuant to conversion of warrants.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories Ltd's Board approved allotment of 1,13,300 equity shares (face value Rs. 10 each) at Rs. 40 per share to two non-promoter warrant holders who exercised their conversion option. Sri Harsha Soma received 80,000 shares and Sailaja Arun Kumar received 31,300 shares. The warrant holders paid the remaining 75% of the issue price (Rs. 30 per warrant) totalling approximately Rs. 39.99 lakh. This is a partial conversion from the 37,29,930 warrants originally allotted on preferential basis on 27th November 2024. The company's paid-up equity capital increased from Rs. 436.86 crore to Rs. 437.99 crore following this allotment.
This is a routine preferential issue conversion with minimal dilution impact (~0.26% dilution based on shares issued). The company's capital base marginally increased, and the warrant conversion brings in fresh equity capital from non-promoter strategic investors.